Biogen pivots to second amyloid-targeted Alzheimer's drug with accelerated approval filing from partner Eisai
Almost exactly a year ago, Biogen CEO Michel Vounatsos boasted that the company’s new Alzheimer’s drug, prepping for billions in sales following its quick FDA …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.